| 2
Forward-Looking Statement
This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private
Securities Litigation Reform Act of 1995, including, but not limited to: our expectations about timing and execution of anticipated milestones,
including the initiation of dosing of FTD-C9orf72 patients, feedback from regulatory of authorities, the progress of clinical studies and the
availability of clinical data from such trials; our expectations about our collaborators’ and partners’ ability to execute key initiatives; our ability to
receive milestone payments from our partners; our expectations about cash runway; and the ability of our product candidates to treat their
respective target CNS disorders. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,”
“estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “possible,” “will,” “would,” and other words and terms of
similar meaning. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such
statements, including: our ability to develop and obtain regulatory approval for our product candidates; the timing and results of preclinical studies
and clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may
arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or
may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; the risk that positive results in a
preclinical study or clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in
later stage clinical trials; failure to protect and enforce our intellectual property, and other proprietary rights; our dependence on collaborators and
other third parties for the development and manufacture of product candidates and other aspects of our business, which are outside of our full
control; risks associated with current and potential delays, work stoppages, or supply chain disruptions; and the other risks and uncertainties that
are described in the Risk Factors section in documents the company files from time to time with the Securities and Exchange Commission (SEC),
and other reports as filed with the SEC. Passage Bio undertakes no obligation to publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. |